United Therapeutics (UTHR) Convertible Debt (2011 - 2013)

United Therapeutics has disclosed Convertible Debt across 3 years of filings, most recently posting $207.4 million for Q1 2013.

• In Q1 2013, Convertible Debt rose 5.41% year-over-year to $207.4 million; the TTM figure through Mar 2013 stood at $207.4 million (up 5.41% YoY), while the FY2012 annual figure was $204.7 million, up 5.4% from the prior year.
• Convertible Debt came in at $207.4 million for Q1 2013 at United Therapeutics, up from $204.7 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $207.4 million in Q1 2013 to a low of $194.2 million in Q4 2011.
• Average Convertible Debt over 3 years is $200.7 million, with a median of $200.7 million recorded in 2012.
• Year-over-year, Convertible Debt grew 5.4% in 2012 and grew 5.41% in 2013.
• Over 3 years, Convertible Debt stood at $194.2 million in 2011, then climbed by 5.4% to $204.7 million in 2012, then advanced by 1.33% to $207.4 million in 2013.
• Per Business Quant data, the three most recent Convertible Debt figures were $207.4 million in Q1 2013, $204.7 million in Q4 2012, and $202.0 million in Q3 2012.